When did SCHOTT Pharma go public?
SCHOTT Pharma AG & Co. KGaA officially completed its initial public offering and began trading its shares on the Frankfurt Stock Exchange under the ticker symbol 1SP on September 28, 2023. As a leading global pioneer in high-quality injectable drug containment solutions—specializing in polymer vials, pre-fillable syringes, and glass ampoules for the pharmaceutical and biotech industries—the enterprise raised hundreds of millions of euros from its market debut, securing vital capital to expand its advanced manufacturing capacity and support cleanroom operations globally.
Related FAQs
Schott AG, a premier international technology group specializing in specialty glass, glass-ceramics, and high-tech optical components, was officially established in Jena, Germany, in 1884.
Sun Pharmaceutical Industries, which launched its initial public offering in March 1994 to raise capital for expanding its domestic manufacturing infrastructure and specialty pharmaceutical operations, priced its equity shares at a nominal face value...
SK Battery America (SKBA) is a premier electric vehicle battery manufacturing enterprise and flagship entity of SK On, producing high-capacity energy cells for leading global automotive brands.
SCHOTT AG operates as a premier international technology group specializing in specialty glass, glass-ceramics, and advanced optical components.
Schott AG is deeply rooted as a classic German high-tech manufacturing enterprise, with its corporate headquarters located in Mainz, Germany.
While the parent enterprise Schott AG remains a privately held foundation-owned corporation, certain specialized subsidiaries within its corporate umbrella—such as Schott Pharma—have been floated as publicly traded entities on public stock exchanges.
Yes, you can buy Oshkosh trucks, often through surplus and government auction platforms.
SCHOTT Pharma corporate email addresses follow structured naming conventions tailored to its global specialty glass and pharmaceutical containment manufacturing operations.
SCHOTT Pharma AG & Co. KGaA trades on Xetra and European exchanges under the ticker symbol 1SXP at €21.90 per share, supporting a market capitalization of approximately €3.31 billion.
SCHOTT Pharma designs, manufactures, and supplies advanced drug containment solutions and delivery systems for the global pharmaceutical and biotechnology industries.
Vice presidents (VPs) and senior technical directors employed by Arcadis—a global design, engineering, and consultancy firm—earn comprehensive executive compensation packages that reflect leadership in infrastructure and environmental management.
A standard 100-unit vial of authentic Botox (onabotulinumtoxinA) manufactured by Allergan typically costs medical practices and aesthetic clinics between 600 and 800 US dollars wholesale per vial.
SCHOTT Pharma AG & Co. KGaA generates trailing twelve-month revenues approaching 991.